Loading Events

« All Events

Oncologic Drug Advisory Committee

July 14

The committee will discuss biologic license application (BLA) 761158, for belantamab mafodotin, submitted by GlaxoSmithKline Intellectual Property Development Ltd. England. The proposed indication for this product is for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform.

Details

Date:
July 14
Event Category: